New pill aims to shrink spleens in rare bone marrow cancer
NCT ID NCT05020652
First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests a new tablet called TQ05105 against a standard drug (hydroxyurea) in 107 adults with moderate or high-risk myelofibrosis, a rare bone marrow disorder. The main goal is to see if TQ05105 can shrink the spleen by at least 35% after 24 weeks of treatment. Participants are randomly assigned to one of the two drugs, and neither they nor their doctors know which they receive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AND HIGH RISK MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510055, China
-
Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
-
West China School of Medicine / West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.